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Inhibitors and promoters of stone formation
HERBERT FLEISCH
Department of Pathophysiology, University of Berne, Berne, Switzerland
Currently, three main mechanisms are thought to
be important in the formation of urinary stones: 1)
the relationship between the concentration of the
precipitating substances in urine and the solubility of
the mineral phase formed, 2) the role of promoters of
crystallization and aggregation, and 3) the part
played by inhibitors of crystal formation and aggre-
gation (Fig. 1).
Saturation of urine
It is now widely accepted that even in normal
people, urine is ordinarily supersaturated with re-
spect to calcium oxalate [1—6], octocalcium phos-
phate [2, 3], hydroxyapatite [1, 2], and sometimes
with respect to brushite [1, 7, 8]. The degree of
supersaturation is usually higher in patients with
urinary stones [2—4, 7—10]. This is due mainly be-
cause these patients tend to excrete more calcium
[10—12], but also because urinary oxalate can be
increased [10, 13]. Urine is also often supersaturated
with respect to sodium urate and ammonium urate
[14, 15]. Supersaturation with regard to magnesium
ammonium phosphate is restricted to the cases
where the urine becomes alkaline because of ammo-
nium production by bacteria [2] (GRIFFITH, this
issue).
Supersaturation can vary in degree. It can be in the
metastable range where precipitation may occur only
when induced by epitaxy or heterogenous nuclea-
tion, or it can be in the unstable region where rapid
spontaneous precipitation does occur. The limit be-
tween the two ranges, which can be called the spon-
taneous formation product, is not a fixed number but
will depend upon the duration of incubation.
These theoretical considerations are relevant to
what occurs in vivo. It was found that when the
urinary saturation measured chemically is above the
spontaneous formation product required for a rapid
induction of precipitation in inorganic solutions,
crystals can usually be detected in the voided urine
specimen [3]. On the other hand, when the ion prod-
uct is below this product, crystals are absent.
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Crystal growth and crystal aggregation
In the past, attention was devoted mostly to the
formation and growth of crystals. Recently, interest
has been directed to an area which, until now, had
been neglected: the crystal aggregation. This term
describes the process of crystals binding one to an-
other, resulting in the formation of larger clusters. In
vitro, aggregation of both calcium oxalate [16, 17]
and calcium phosphate crystals [18] occurs readily
when the solution is supersaturated. Aggregation
could be the mechanism which distinguishes simple
crystalluria, which occurs in most normal people,
from stone formation. This line of thought is
strengthened by the finding that while usually only
individual calcium oxalate crystals are found in nor-
mal people, stone-formers often excrete large aggre-
gates of this salt [16, 19].
Promoters of crystallization
A few years ago, great emphasis was placed on the
supposed activating role of organic compounds in
urine [20]. This was based on the finding that urinary
proteins bind calcium [21] and can induce calcifica-
tion in vitro [22] under certain conditions. Further-
more, proteins are increased in amount [22, 23] and
are qualitatively different [24, 25] in urine samples
from stone-formers than in that from normal people.
Such an activating theory was invoked to account for
the close morphological relation existing between the
matrix and the mineral in the stones [26, 27]. All
these results, however, give no evidence that the
change in the urinary proteins is the primary event in
stone formation. Indeed, they just as well might be
secondary to the irritation from the stone and to
infection. The morphological relation between ma-
trix and mineral could be due to a co-precipitation of
the proteins with the mineral or their secondary
binding onto the crystals [28]. Lately, the theory of
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Fig. 1. Mechanisms of mineral formation. Inhibition of crystal
growth is denoted by open arrows; inhibition of crystal aggrega-
tion is denoted by the large closed arrows.
the activating role of urinary proteins has been aban-
doned by most investigators. As such a role, how-
ever, could not be proven, it also has not been
disproven.
In recent years, emphasis has been shifted towards
the role of crystals of one salt inducing the crystalli-
zation of a salt of another nature. Such an epitactic
induction between crystals having similarities in lat-
tice dimensions is a well known phenomenon in
crystallography. Relevant lattice similarities are
present between uric acid, calcium oxalate, and cal-
cium phosphate crystals [29], and epitactic induction
does occur among them. Thus, the precipitation of
sodium urate is favored by both hydroxyapatite and
calcium oxalate [30]. The precipitation of calcium
oxalate can be induced from a metastable solution by
hydroxyapatite [30, 31], brushite [30], and urate [30,
32, 33] but not consistently by uric acid [30, 33] (see
Dr. Coe's article, this issue). Conversely, calcium
phosphate precipitation is stimulated by both cal-
cium oxalate and monosodium urate crystals [30,
33], while uric acid is not effective [30, 33]. Interest-
ingly, this effect of calcium oxalate on calcium phos-
phate precipitation is not as efficient as the reverse
[31]. This might be because hydroxyapatite is not the
first salt to form when calcium phosphate precipi-
tates, but is preceded by other phases, the nature of
which is still disputed. These initially formed phases
spontaneously transform into the more stable
hydroxyapatite.
This epitactic mechanism of precipitation could
give an explanation for the well known fact that most
stones are formed not just by one salt but by a
mixture of different kinds of salts. It could also
explain the clinical findings that patients with cal-
cium stones are often hyperuricosuric [34] and that
treatment with allopurinol, which decreases the ex-
cretion of urate, reduces the formation of calcium
stones [34, 35] (see COE, this issue).
Inhibitors of crystallization
Since urine usually is supersaturated with respect
to the various stone-forming salts and contains crys-
tals, the conditions for crystal formation, aggrega-
tion, and thus stone formation are satisfied. Thus,
the main question is not why stones can form but
why stones do not form more generally. One expla-
nation might be the presence in urine of very effec-
tive inhibitors for both these processes, crystal for-
mation and aggregation.
Inhibitors of ihe formation of calcium phosphate
Chemical estimation of inhibitory activity. One of
the first techniques testing urine's inhibitory capacity
[36, 37] made use of a system, described in the
1930's, for studying the calcification of cartilage [38].
Epiphyseal cartilage from rachitic rats was incubated
in vitro in a supersaturated salt solution, and the
precipitation of calcium phosphate was studied. Ur-
ine or the substances to be tested are added to the
incubation fluid. The results, however, are difficult
to interpret. Since the cartilage is enzymatically very
active, it is likely to destroy certain inhibitors. Fur-
thermore, the test substance or urine may influence
the enzyme activity as well as the metabolic ma-
chinery of the incubating cartilage, thereby altering
the precipitation by a mechanism unrelated to crystal
growth inhibitors [39]. Obviously, the results ob-
tained can be totally unrelated to stone formation,
and the technique, while possibly useful for cartilage
calcification, should be abandoned for the study of
stone formation.
A theoretically correct approach of practical im-
portance is the determination in vitro of the mini-
mum product of calcium x phosphate (formation
product) necessary for the formation of a solid phase
within a preset time period under defined conditions.
The experimental conditions of this technique, which
measures mainly heterogenous nucleation (see FIN-
LAY5ON, this issue), are critical and need to be care-
fully controlled. For example, the time of incubation
has an inverse effect: the shorter the time of incuba-
tion the greater the formation product [40]. Inhibi-
tors will increase this product. It has been reported
that inhibitors are not active at very short incubation
times, and that they increase the formation product
value only up to that obtained at short incubation
times [40]. It has been suggested that this occurs
because homogenous nucleation is predominant ini-
tially, and is later replaced by heterogenous nuclea-
tion. However, as discussed in Finlayson's article
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(this issue), it is unlikely that homogenous nucleation
could proceed in complex solution such as urine.
Moreover, the report showing the independence of
formation product from inhibitor activity has not
been confirmed [411.
It must be kept in mind that the determination of
the formation product does not measure specifically
an effect on the formation of the final phase, since in
some cases there is first one salt formed which then
transforms into a salt of another type [421. Thus, an
inhibitor acting on the growth of the second salt
might be missed since the first will be formed nor-
mally. The nature of the first phase is still disputed.
Amorphous calcium phosphate [43, 44], brushite
[45—471, octocalcium phosphate [40, 45, 48, 49] are
some of the proposed forms.
The formation product can also be determined in
the presence of a nucleating agent of some kind, such
as collagen 150], elastin, or crystals of another salt.
Nucleating agents will decrease the formation prod-
uct for a given incubation time and permit the detec-
tion of inhibitory activity at shorter incubation times.
While very useful to investigate the effect of indi-
vidual compounds, the determination of the forma-
tion product presents problems when used to test
urine. In urine, one must measure the thermody-
namic product of the ion activities and not just the
simple calcium x phosphate product. Various means
have been investigated to determine this product.
One is to determine chemically all the ions and com-
plexes involved and to calculate their activities in the
urine using the chemical stability constants described
in the literature [2]. This procedure is tedious and
probably not without error, since some of the stabil-
ity constants are still doubtful [51]. A simplified
approach has been suggested which consists of mea-
suring the formation product as the ionic concentra-
tion of calcium times phosphate (Ca2 x HPO, or
Ca >< P1) at the limit of metastability and relating it to
the solubility of brushite (CaHPO4 2H2O) in the
individual urine [47, 52, 53]. This "formation prod-
uct ratio" gives an estimate of the minimum supersa-
turation (given as number of times saturated) re-
quired to induce nucleation of brushite [9, 47].
A further problem when measuring the formation
product in whole urine is that the measurement of
inhibitor activity may not be sensitive enough. This
drawback could be solved by using smaller concen-
trations of urine in the test system. An amount of a
few percent is still very effective, and at these small
concentrations, the system is much more sensitive
[54]. This dilution of the urine has also the advantage
of making the influences of changing ionic strength
and ion complexing negligible. Unfortunately, the
measurement of inhibitory activity in diluted urine
may not be representative of whole urine. Since
inhibitory activity is generally not related linearly
with its concentration, and since the concentration-
effect relation is different for the various inhibitors,
their relative importance will change with dilution.
Furthermore, urine itself can influence the effect of
certain inhibitors so that an effect can be different in
inorganic solutions, diluted urine, and whole urine.
Another approach which measures mainly crystal
growth is to measure the kinetics of the precipitation
of the mineral after addition of a seed to trigger the
reaction. Calcium phosphate [55] or other nucleating
materials are added to a solution with a defined
supersaturation, and the decrease in the solution of
calcium or phosphate concentration or both are mea-
sured. At acid pH, where brushite is formed, the rate
of crystal growth is proportional to the square of the
supersaturation, allowing one to calculate readily the
rate of crystal formation [56]. Unfortunately, at
higher pH, where salts other than brushite are
formed, the precipitation curve obtained is more
complex and cannot be analyzed quantitatively,
probably because of the formation of precursor
phases which later transform into more stable ones,
especially apatite [42, 55]. Unfortunately, it is these
conditions which are likely to be more relevant phys-
iologically, since although brushite is thought by
some to be the first salt to form in calcium phosphate
stones [47, 57], it is normally not found in the formed
stones. A simplified version of this approach is to
determine just the amount of calcium salt formed
within one chosen time [9, 46, 57—60].
In both these approaches it is important that the
supersaturation level is well defined. As discussed by
Finlayson (this issue), in whole urine, the compari-
son of the ratio of the Ca x P1 versus the Ca x P,
measured after incubating with brushite, is probably
the most convenient method [9, 51].
Recently, we have worked out a new method
based on the determination of the amount of seed
crystals needed to induce a certain amount of precip-
itation in the urine specimen [1331. This amount will
reflect the amount of inhibitor present in the urine.
The Ca x P1 product of the urine is adjusted to the
solubility of brushite, therefore at a constant calcium
x phosphate activity product. Calcium apatite, the
solubility of which is much below that of brushite
[611, is then added, and the minimum amount of
apatite necessary to initiate a precipitation of 50% in
a predetermined time is measured.
Nature of the inhibitory activity. Much work has
been devoted to the identification of the various
inhibitors since they are likely to be important not
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only in stone formation but also in the process of
normal and pathological calcification. It has been
known for nearly 20 years that urine contains sub-
stances capable of inhibiting calcium phosphate de-
position [36, 62]. The first of these inhibitors to he
isolated and identified from urine was inorganic
pyrophosphate [541. This compound has been shown
to be very powerful in all of the test systems. Inor-
ganic pyrophosphate increases strongly the mini-
mum Ca x P, product necessary to form a precipita-
tion [50, 541; it diminishes the rate of precipitation
upon added crystals of brushite [631, octocalcium
phosphate [64], and apatite 165, 661, inhibits the
precipitation induced by nucleators such as collagen
[46, 50, 58, 59, 67], increases the amount of apatite
crystals needed to induce the precipitation of cal-
cium phosphate [133], and inhibits the calcification
of cartilage [68, 691. Finally, pyrophosphate inhibits
the transformation of amorphous calcium phosphate
into its crystalline form [70, 711. The amount of
pyrophosphate excreted daily lies between 10 and 60
moles. The concentration is in the range of 10 to
10 M [72, 73], enough to exert a strong, sometimes
even a maximal inhibition in the various tests used.
Other compounds such as magnesium [57, 59, 66,
69, 74], zinc [39], fluoride [57, 59, 75, 76] (although
in some conditions, this ion can also activate the
precipitation [75, 76]), stannous ions [751, and citrate
[66, 1331 are able to inhibit the precipitation of cal-
cium phosphate under certain conditions. Besides
these known substances, there are possibly other yet
unidentified components present in urine which in-
hibit the formation of calcium phosphate [54, 66, 77,
78]. For a time, these inhibitors were thought to be of
peptidic nature [58, 77—79], a theory which has re-
cently been abandoned, the compounds studied
being probably contaminants [661. Recently, phos-
phocitrate has been implicated (see THOMAS, this
issue).
The question of the role played by the various
compounds in the total inhibitory activity is not yet
answered. One difficulty is due to the fact that the
relation depends on the dilution of the urine tested,
as well as on the technique used to measure the
activity. The fact that pyrophosphate is the main
inhibitor at a concentration of two percent urine [54]
does not necessarily mean that this compound is also
the main inhibitor in whole urine. Even when using
whole urine, results may vary according to whether
the test utilized measures principally crystal growth
or nucleation (formation product). When examined
in the system where the amount of apatite needed for
inducing the precipitation of this salt is determined,
pyrophosphate was found to represent only about
10% of the total activity while magnesium repre-
sented 20% and citrate represented about 50% [133].
In this test, 20% inhibition was due to unknown
compounds. This percentage increases in other as-
says, especially when the urine is diluted [54]. While
it appears undisputed that test systems using whole
undiluted urine are more relevant to what occurs in
urine during stone formation, it is not possible to
decide at the present time which of them is the most
representative one.
Recently, efforts have been devoted to finding
inhibitory compounds exogenous to normal urine,
but which would be excreted after oral administra-
tion. The fact that not only pyrophosphate, but also
polyphosphates [50], ATP [50], phosphorylated in-
ositols [67], as well as compounds characterized by a
P-N-P bond, the imidophosphates [801, were found
to be very effective inhibitors, raised the possibility
that other P, compounds, related in structure, but
resistent to enzymic hydrolysis could be found and
used therapeutically. The phosphonates, character-
ized by C-P bonds and, more specifically, the diphos-
phonates (P-C-P) seemed very promising. Diphos-
phonates are entirely resistant to breakdown in the
body and were found by many authors to be very
effective in a variety of test systems [41, 59, 60, 71,
81, 82].
Inhibitors of the aggregation of the calcium phosphate
c,ystals
Recently, attention has been given to a process
which has been relatively ignored up to now, that of
crystal aggregation, i.e., the binding of individual
crystals into larger aggregates. This approach devel-
oped from the observation that stone-formers tend to
excrete in their urine large aggregates of oxalate
crystals, while normal people excrete only individual
crystals [19]. It was then studied extensively for this
salt [16, 17, 83—85].
Aggregation occurs also with calcium phosphate
crystals. When individual apatite crystals are incu-
bated in slightly metastable solution, they will tend to
bind to larger clusters. This process can be measured
quantitatively by counting the number of "particles"
of various sizes with a Coulter counter [18]. Urine
inhibits this process very efficiently [18]. Unfortu-
nately, while the inhibitors can be measured in di-
luted urine, no technique exists yet for the measure-
ment in whole urine. Citrate, pyrophosphate, and the
diphosphonates, and interestingly, also the glycos-
aminoglycans, especially heparin, hyaluronic acid,
and dermatan sulfate are inhibitory [18]. The fact
that these glycosaminoglycans are ineffective at
Inhibitors and promoters of stones 365
these concentrations on crystal formation [50] shows
that the two processes, crystal growth and aggrega-
tion, seem to be favored by different factors. Methyl-
ene blue, which has been suggested to be useful in
prevention of renal stones [86], has no effect [18].
Since the inhibitory activity of urine is to a large part
not filtrable through a 50,000 mol wt filter 1118], it is
possible that the nonfiltrable part is due to glycos-
aminoglycans. This would bring back the old theory
of the presence in urine of so-called "colloid protec-
tors" [87].
Of interest is finally the fact that diphosphonates
and heparin also induce the disaggregation of already
aggregated crystals [881. This could possibly be of
importance in urine leading to disrupture of already
formed aggregates.
Inhibitors of the formation of calcium oxalate
Chemical estimation of inhibitory activity. The
quantitative methods to determine the inhibitors of
calcium oxalate precipitation are similar to those
described for calcium phosphate. They include the
measurement of the minimum Ca >< oxalate product
necessary for crystal formation both in diluted [89]
as well as in whole urine [90, 91]. For the latter, the
ratio of Ca x oxalate formation product vs. the Ca X
oxalate product after equilibration with solid calcium
oxalate has been used to determine the limit of me-
tastability (formation product ratio) [91].
The other approach, namely to determine the rate
of precipitation after addition of a seed, has been
very fruitful and extensively used. Indeed, with cal-
cium oxalate, the kinetic analysis of the crystal
growth is much more straight forward than for cal-
cium phosphate. The reaction is controlled by a
bimolecular surface reaction and is thus of second
order. The rate of disappearance of each ion being
proportional to the square of the supersaturation
[921, the disappearance thus can be analyzed easily
quantitatively and the rate constants determined.
The influence of various substances as well as of
urine on the rate of crystal growth therefore can be
determined quantitatively [931. Unfortunately, the
measurements up to now only have been done on
diluted urine [93]. Whether the extrapolation of re-
sults obtained at various urine dilutions can be ex-
trapolated to full urine has not been proven yet.
A simplified version of this approach is to set the
supersaturation in a straight solution or whole urine
to a known level, and to determine to what extent
precipitation has occurred, either in the solution or
on a nucleator such as a glass rod or a wire after a
defined time lapse [5, 9, 90, 91, 94—98]. While this
technique is acceptable in straight solutions with
defined ion concentrations, it is valid in whole urine
only if the supersaturation can be determined [9].
Nature of the inhibitory activity. As for calcium
phosphate, urine has been found to inhibit strongly
the precipitation of calcium oxalate [93, 94, 96]. The
same is true for pyrophosphate [32, 83, 90, 93, 95,97,
99, 100], citrate, and magnesium [93], as well as for a
great number of substances, i.e., dyes [95, 97] (e.g.,
methylene blue [102]), phytate [95], polyelectrolytes
[95], urinary macromolecules [90], and especially
metals [95, 97, 101] and heparin [103]. As for cal-
cium phosphate, it is still difficult to evaluate what is
the relative part played by the various known inhibi-
tors. This question is especially difficult to answer
since many compounds can have different activities
when tested in simple solutions or in urine. Thus,
from the many compounds known to inhibit growth
of calcium oxalate, only very few have been found to
be effective also in whole urine [97]. One of them
was inorganic pyrophosphate. It would appear,
nevertheless, that at least in the system measuring
the rate of precipitation, the known inhibitors repre-
sent only a small portion of the total inhibitory activ-
ity present [93].
In analogy to calcium phosphate, among the non-
physiological compounds, the diphosphonates are
probably the most powerful inhibitors of calcium
oxalate precipitation found up to the present time
[91, 99, 104].
Inhibitors of the aggregation of calcium oxalate crystals
An interesting new approach to the problem of
stone formation is the role played by the process of
calcium oxalate crystal aggregation. As mentioned
above, it appears that stone-formers are more prone
to excrete aggregates than normal people [16, 19],
and there is an actual correlation between the excre-
tion of large clusters and the rate of stone formation
[4].
Techniques have been devised to measure aggre-
gation in vitro [16, 17, 83, 85]. Disaggregated oxalate
crystals are incubated in a slightly supersaturated
solution, and the development of crystal clusters
which occur spontaneously with time are measured.
When urine is added to the system, the aggregation
of calcium oxalate crystals is strongly inhibited [16,
17, 85]. Unfortunately, it has not been possible to
develop the measurement of this inhibition in whole
undiluted urine, since addition of calcium oxalate
induces precipitation of other salts.
Pyrophosphate, diphosphonates, and glycos-
aminoglycans, especially heparin and chon-
droitin sulfate, were found to inhibit very strongly
the aggregation of calcium oxalate [17, 84, 85, 105].
366 Fleisch
Methylene blue had no effect [84]. Diphosphonates
are active inhibitors also when given in vivo [105].
The effect of pyrophosphate and the diphosphonates
increase at alkaline pH, while the effect of urine is
not pH-dependent [85].
It has been difficult up to now to assess the amount
of the total inhibition played by the various parts.
Some data indicates that pyrophosphate would ac-
count for about 15% of the total activity [1061. A
large part would be due to a macromolecule of large
molecular weight [85, 107] which is precipitated by
cetyl pyridinium chloride, which suggests that it
could be a glycosaminoglycan [106].
Mechanism of the inhibitory activity
Most of the work on the mode of action of the
relevant inhibitors has been done on pyrophosphate
and diphosphonates. These compounds were found
to delay the various processes involved in the forma-
tion of the solid phase, namely epitactic or heteroge-
nous nucleation, crystal growth, crystal aggregation,
and phase transformation from the amorphous to the
crystalline form. These various effects appear to be
related to the binding of the inhibitors onto the crys-
tal surface where they inhibit induction of new crys-
tals, growth, and aggregation. The relation between
the absorption of substances onto the crystals and
their effect on crystal growth is a well known phe-
nomenon. Many compounds, called crystal modi-
fiers, can inhibit the crystal growth of certain salts,
and there is a close correlation between the concen-
tration of the compounds on the crystal surface and
the degree of inhibition [108]. It is not necessary,
however, for the whole surface to be covered by a
macromolecular layer in order to obtain an inhibi-
tion. Specific binding onto the sites of crystal growth
will suffice, so that an inhibition is obtained when
less than one percent of the surface is covered.
Pyrophosphate and diphosphonates have both
been shown to be bound strongly onto the crystals of
hydroxyapatite [109—111]. The amount bound can be
very large (for pyrophosphate, about two molecules
per surface unit cell [109, 111]), and is accompanied
by a displacement of orthophosphate [111—113].
From the results obtained by Scatchard plots, it
appears that the binding is not restricted to a single
class of binding sites with constant affinity [111].
Interestingly, the affinity to the first site goes in
parallel with the inhibitory activity of crystal forma-
tion [1111, suggesting it represents binding onto the
sites responsible for crystal growth. It is likely that
the binding occurs through a calcium ion. A further
support for such a surface controlled mechanism is
the fact that inhibition of the formation rate of brush-
ite [63] and calcium oxalate [93] follows the laws of
the Langmuir adsorption isotherms. Inhibition of ag-
gregation, on the other hand, is more likely to be due
to a change in the zeta potential of the surface, which
will alter attraction or repulsion between crystals.
Inhibitors in patients with urinary stones
The question as to whether stone formers have
less inhibitors in their urine is still not completely
settled, although there is now strong evidence that
many patients do show such a defect. This uncer-
tainty may be attributed partly to the wide variety of
techniques used, insufficient data available from
study of whole urine, and the failure often times to
obtain control groups, matched with respect to age,
sex, and diet.
A decrease of inhibitory activity of calcium phos-
phate precipitation has been described in stone-for-
mers, using the rat cartilage system [36, 37, 68, 74].
A decrease has also been found using the determina-
tion of the Ca x P1 formation product, either in
presence of diluted urine [1341 or in whole urine [91.
For calcium oxalate, a decrease in inhibitors was
detected, using the determination of the formation
product [91, as well as the crystallization [5, 9, 94] in
whole urine. A decrease in inhibition of calcium
oxalate aggregation has been described in urine of
stone patients [4, 16, 114]. This is especially the case
in patients presenting a relatively smaller urinary
calcium x oxalate supersaturation, so that when
both parameters, supersaturation and inhibition of
aggregation, are taken into account stone-formers
and controls can be very clearly separated [1141.
Various data indicates that pyrophosphate is de-
creased in stone-formers [73, 115, 116], although
such a decrease has not been found by all investiga-
tors [691. The observed difference seems to occur
mainly in middle-aged men [73], a group in which
stone formation is actually most frequent, and in the
patients without hypercalciuria [116]. The lack of
pyrophosphate becomes more apparent when pa-
tients are matched to control with respect to age,
sex, and diet, in which condition, a diminution of
50% has been observed in men [134]. Women, how-
ever, showed no abnormality.
Until now, only a few ways to increase urinary
inhibitors are known. As will be discussed in Dr.
Thomas's article (this issue) one of them is the oral
administration of orthophosphate, which will in-
crease the excretion of pyrophosphate [117, 118].
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Cellulose phosphate, however, does not [52]. Ortho-
phosphate administration decreases both calcium ox-
alate and calcium phosphate aggregation in urine
[119]. Furthermore, it is claimed by many [120—
124], although not accepted by all [125, 1261, to be
efficient in the treatment of recurrent calcium stones.
All these effects could be explained at least partly by
the increase in urinary pyrophosphate, although the
decrease in calciuria which occurs and which de-
creases in turn the urinary saturation vs. calcium
oxalate [1191 is also likely to play a role. The satura-
tion vs. calcium phosphate, however, is not altered
[119] nor is it increased [52]. Recently, thiazide,
which has been proposed in the treatment of stones
because it decreases urinary calcium [34, 127], has
been shown to increase the formation product in
whole urine both of calcium oxalate [128] and brush-
ite [129]. This effect is probably due to the increase
of pyrophosphate following the increase in ortho-
phosphate excretion. As will be discussed in the
article by Yendt and Cohanim (this issue), renal
excretion of other inhibitors, such as zinc, may be
increased as well.
The parallelism between the excretion of ortho-
phosphate and pyrophosphate is probably due to a
direct action of orthophosphate on the kidney. In-
deed, the oral administration of orthophosphate
causes a rapid increase in the renal clearance of
pyrophosphate without a change in the blood con-
centration [130]. Furthermore, as shown in studies
with dogs, the unilateral infusion of orthophosphate
into one kidney causes a greater and more rapid
increase in the infused kidney than in the noninfused
one [1301.
The powerful effects of the diphosphonates on the
formation and aggregation of calcium phosphate and
calcium oxalate crystals and the fact that they are
excreted in the urine after oral administration raised
the possibility that these compounds might be useful
in the treatment of urinary stones. In animal studies,
they were found when given orally to decrease the
formation of experimentally induced bladder stones
[104]. In man, the oral administration of ethane-l-
hydroxy-1,1-diphosphonate (EHDP) decreases the
amount of calcium oxalate crystal aggregates [1051,
increases the formation product of calcium phos-
phate when tested in diluted urine [131], and de-
creases the growth of brushite in full urine [132].
Clinically, it appeared to decrease the recurrence of
stones [131]. However, the dosage needed to be
effective was at a level where an effect on bone
turnover and mineralization was likely, so that its
use does not seem to be warranted. The develop-
ment of a phosphonate which is excreted in urine but
does not enter bone might solve this problem.
In the studies of stone formation, it is necessary,
however, to keep in mind that urolithiasis is most
probably a multifactorial disease. Several predispos-
ing factors, such as hypercalciuria, hyperoxaluria,
hyperuricosuria, urinary infection, deficiency of in-
hibitors of crystal formation, and deficiency in inhibi-
tors of crystal aggregation can play a role. Not all are
likely to be present in the same patient, so that it will
become necessary to divide the patients into
subgroups, according to their pathophysiological dis-
turbance. The same is likely to be true for the treat-
ments. A specific treatment for one disturbance can
be beneficial in this group, but possibly not in others.
This basic principle is frequently disregarded which
explains why the treatment is most often far from
satisfactory.
Summary
The understanding of the formation of urinary
stones centers around three main mechanisms: the
urinary concentration of stone-forming ions, the role
of promoters, and the role of inhibitors of crystal
formation and crystal aggregation. With respect to
the promoting activity, lately emphasis has shifted
from the role of the organic matrix to that of one salt
inducing by epitaxy the precipitation of another salt.
Among the inhibitors, it has become necessary to
distinguish between those affecting crystal formation
and those affecting crystal aggregation. For measur-
ing the inhibitory activity, the various techniques and
their relevance have been reviewed. It has been
found that the main inhibitors for calcium phosphate
and calcium oxalate precipitation are citrate, pyro-
phosphate, and perhaps magnesium. Those for cal-
cium phosphate and calcium oxalate aggregation are
glycosaminoglycans, pyrophosphate, and citrate.
Among the synthetic inhibitors, the diphosphonates
are the most powerful for both processes. The role
and the therapeutic implications of these various
concepts have been discussed.
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